http://pharmexec.findpharma.com/pharmexec/Strategy/Article/list/43776 The art and science of running a successful pharmaceutical company. 2009-11-20T23:46:21Z http://pharmexec.findpharma.com/pharmexec/Strategy/Lean-Comes-to-Pharma/ArticleStandard/Article/detail/641195?contextCategoryId=43776&ref=25 The business philosophy and tools that revolutionized Toyota could save the ailing drug industry a lot more than just time and money. But is pharma really capable of getting lean? 2009-11-18T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/462009/641195/efficient_thumbnail.jpg http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/462009/641195null XML http://pharmexec.findpharma.com/pharmexec/Strategy/Are-You-Ready-For-The-Revolution/ArticleStandard/Article/detail/631737?contextCategoryId=43776&ref=25 Seven Global Trends shaping the future of the pharmaceutical industry. 2009-11-11T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/412009/631737/Picture-11_thumbnail.jpg http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/412009/631737null XML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Pfizer-Quick-on-the-Draw-with-RampD-Location-Plans/ArticleStandard/Article/detail/640996?contextCategoryId=43776&ref=25 Following through with its promise to waste no time in merging Wyeth and Pfizer, the pharma giant announced restructuring plans for its global research network. 2009-11-11T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/462009/640996null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/GSK-Donates-50-Million-H1N1-Doses-To-WHO/ArticleStandard/Article/detail/640997?contextCategoryId=43776&ref=25 Developing countries will receive the scarce vaccine for free, as GSK remains confident it will fulfill contractual vaccine obligations around the world. 2009-11-11T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/462009/640997null HTML http://pharmexec.findpharma.com/pharmexec/Marketing/Applying-FDA-Regulations-to-Online-Marketing/ArticleStandard/Article/detail/640297?contextCategoryId=43776&ref=25 This guide aims to provide pharma marketers with an overview of the key challenges surrounding Direct-to-Consumer (DTC) online marketing and some potential solutions for effectively leveraging this channel within the complex regulatory environment. 2009-11-09T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/462009/640297null REMOTE http://pharmexec.findpharma.com/pharmexec/Deals/Glaxo-Vies-for-a-Second-Act-in-HIV/ArticleStandard/Article/detail/639343?contextCategoryId=43776&ref=25 A novel joint venture between Glaxo and Pfizer is big on promise. But the combined portfolio and pipeline of HIV drugs? Not so much. 2009-11-04T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/452009/639343null HTML http://pharmexec.findpharma.com/pharmexec/R%26D/Innovation-Over-Imitation/ArticleStandard/Article/detail/631735?contextCategoryId=43776&ref=25 As the first generation of biologics patents expire, companies are jokeying for position in follow-on biologics. 2009-11-04T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/412009/631735/Picture-9_thumbnail.jpg http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/412009/631735null XML http://pharmexec.findpharma.com/pharmexec/News+Analysis/JampJ-Cuts-Staff-in-Major-Restructuring-Move/ArticleStandard/Article/detail/639344?contextCategoryId=43776&ref=25 Johnson & Johnson announced a massive restructuring plan on Tuesday in an effort to save $1.4 billion to $1.7 billion by 2011. The human cost: 7 percent of its workforce. 2009-11-04T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/452009/639344null HTML http://pharmexec.findpharma.com/pharmexec/Strategy/Global-Pharma-Market-Growth-to-Grow-4-to-6-Percent/ArticleStandard/Article/detail/632250?contextCategoryId=43776&ref=25 Sure, industry growth is at "historically low levels," but at least pharma is still growing. The industry's market value should surpass $825 billion in 2010, and forecasted growth was bumped up one percentage point from original estimates. 2009-10-08T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/412009/632250null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/H1N1-Vaccine-Hits-the-Market/ArticleStandard/Article/detail/632251?contextCategoryId=43776&ref=25 Pulling off an incredibly fast turnaround, the pharma industry has released a vaccine for the H1N1 virus, bolstering its bottom line with a second flu vaccine and potentially helping millions of people. So why is there such an uproar over whether it's safe? 2009-10-07T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/412009/632251null HTML http://pharmexec.findpharma.com/pharmexec/Strategy/The-Book-on-Daniel/ArticleStandard/Article/detail/631739?contextCategoryId=43776&ref=25 Novartis CEO Daniel Vasella has built the Swiss firm into the fastest growing pharma in the world, and in the process gained a reputation as an outspoken visionary. But is he really as good as all that? 2009-10-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/412009/631739/Picture-12_thumbnail.jpg http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/412009/631739null XML http://pharmexec.findpharma.com/pharmexec/News+Analysis/iPharm-Execi-QampA-GSKs-Deirdre-Connelly/ArticleStandard/Article/detail/630329?contextCategoryId=43776&ref=25 Just months on the job and GSK’s new president of North American Pharmaceuticals Deirdre Connelly is already making her presence known. Her latest move—spearheading an initiative that will boost funding to autonomous CME programs and cut commercial medical education programs. Pharm Exec spoke with Connelly to find out more. 2009-09-30T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/402009/630329null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Lilly-Shuffles-Staff-Cuts-Thousands-of-Jobs/ArticleStandard/Article/detail/626469?contextCategoryId=43776&ref=25 Eli Lilly announced this morning that it would eliminate approximately 5,500 positions as part of a massive reorganization strategy that's expected to net the firm reduce $1 billion in costs by 2011. 2009-09-14T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/382009/626469null HTML http://pharmexec.findpharma.com/pharmexec/Profiles/A-Different-World/ArticleStandard/Article/detail/625739?contextCategoryId=43776&ref=25 Brent Saunders, Schering-Plough's president of global consumer healthcare, talks growing role of OTC drugs in Pharma's future. 2009-09-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/372009/625739null XML http://pharmexec.findpharma.com/pharmexec/Noteworthy/One-Pill-Makes-You-Small/ArticleStandard/Article/detail/625748?contextCategoryId=43776&ref=25 The obesity pipeline, despite a hugely underserved market potentially worth $11 billion, is awfully thin. 2009-09-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/372009/625748/obesity_thumbnail.jpg http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/372009/625748null XML http://pharmexec.findpharma.com/pharmexec/Strategy/Industry-Audit-2009/ArticleStandard/Article/detail/625744?contextCategoryId=43776&ref=25 Bill Trombetta expands his annual guide to stellar performance with the "Heavenly 27." 2009-09-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/372009/625744/calculator_thumbnail.jpg http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/372009/625744null XML http://pharmexec.findpharma.com/pharmexec/Web+Exclusives/This-Is-Going-to-Hurt/ArticleStandard/Article/detail/618558?contextCategoryId=43776&ref=25 The President and Congress are sounding the alarm on the need for healthcare reform. There are several near-certainties for which pharmaceutical and biotechnology companies must be prepared as they develop forecasts and for the next five or six years. 2009-08-12T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/332009/618558null HTML http://pharmexec.findpharma.com/pharmexec/Noteworthy/Whats-the-Deal-at-Solvay/ArticleStandard/Article/detail/616637?contextCategoryId=43776&ref=25 The Belgian drugmaker is pursuing a sale, inking deals, issuing debt, and launching a power drug for Parkinson's—all at once. 2009-08-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/322009/616637/PE0809_solvay_thumbnail.jpg http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/322009/616637null XML http://pharmexec.findpharma.com/pharmexec/Noteworthy/Betting-the-Pharma/ArticleStandard/Article/detail/616636?contextCategoryId=43776&ref=25 With the biotech industry reeling from the recession, big drugmakers hold all the cards when it comes to making deals, but picking a winner is still a gamble. Here are 10 to place stakes on. 2009-08-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/322009/616636/PE0809_M&A_thumbnail.jpg http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/322009/616636null XML http://pharmexec.findpharma.com/pharmexec/Web+Exclusives/Prepare-Now-to-Avoid-the-Burn/ArticleStandard/Article/detail/611852?contextCategoryId=43776&ref=25 The sponsors of clinical trials Sunshine Act legislation to improve their physician payment processes, educate the public on the complexity of clinical research and development, and help patients make informed opinions about physicians - bringing true transparency to the financial aspects of discovering new medical treatments. 2009-07-16T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/292009/611852null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Sanofi-Gets-Green-Light-on-Blockbuster-Heart-Treat/ArticleStandard/Article/detail/609625?contextCategoryId=43776&ref=25 Sanofi-Aventis is banking that its highly anticipated atrial fibrillation/flutter treatment Multaq will be a huge success. The path to approval has been ridden with a failed trial and a very long review process, but for Sanofi, the wait has been worth it. 2009-07-08T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/282009/609625null HTML http://pharmexec.findpharma.com/pharmexec/Noteworthy/The-Pharmerging-Future/ArticleStandard/Article/detail/608960?contextCategoryId=43776&ref=25 A guide to grabbing growth in seven "pharmerging" markets. 2009-07-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/282009/608960/PE0709_pharmerging_thumbnail.jpg http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/282009/608960null XML http://pharmexec.findpharma.com/pharmexec/Noteworthy/French-Revolution/ArticleStandard/Article/detail/608966?contextCategoryId=43776&ref=25 Chris Viehbacher's first fast and furious six months at the top of Sanofi-Aventis have heads spinning...and rolling. 2009-07-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/282009/608966/PE0709_viebacher_thumbnail.jpg http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/282009/608966null XML http://pharmexec.findpharma.com/pharmexec/Strategy/Oscient-Pharmaceuticals-Lays-Off-180-Reps/ArticleStandard/Article/detail/604392?contextCategoryId=43776&ref=25 Oscient trims 180 sales, marketing, and corporate jobs in the wake of patent expirations, generic competition. 2009-06-17T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/252009/604392null HTML http://pharmexec.findpharma.com/pharmexec/Special+Reports/Emerging-Leaders-2009-The-Faces-of-Innovation/ArticleStandard/Article/detail/603281?contextCategoryId=43776&ref=25 Our second annual Emerging Leadership Awards cast the spotlight on 27 young rising stars most notable for their dedication and contribution to the pharma industry. Here's a closer look at why. 2009-06-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/242009/603281/PE0609_ELA_thumbnail.jpg http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/242009/603281null XML http://pharmexec.findpharma.com/pharmexec/Noteworthy/Stealth-Pharmas/ArticleStandard/Article/detail/603289?contextCategoryId=43776&ref=25 The third annual audit reveals how pharma's "other half" performs. 2009-06-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/242009/603289/PE0609_stealth_thumbnail.jpg http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/242009/603289null XML http://pharmexec.findpharma.com/pharmexec/Noteworthy/Pay-For-Play/ArticleStandard/Article/detail/603303?contextCategoryId=43776&ref=25 The P4P movement is here. Pharma marketers, it's time to take note. 2009-06-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/242009/603303/PE0609_P4P_thumbnail.jpg http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/242009/603303null XML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Amylin-Drops-200-Sales-Reps/ArticleStandard/Article/detail/597346?contextCategoryId=43776&ref=25 As it readies submission for a once-weekly diabetes injectable, Amylin announces that it will trim 35 percent of its sales force and put focus on specialty physicians. 2009-05-07T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/192009/597346null REMOTE http://pharmexec.findpharma.com/pharmexec/Online+Only/Bio-Companies-Low-on-Venture-Capital-Cash/ArticleStandard/Article/detail/596953?contextCategoryId=43776&ref=25 As the economy continues to retract, fewer biotech companies are finding the funding they need to survive, driving more firms to sell or close shop. 2009-05-06T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/192009/596953null HTML http://pharmexec.findpharma.com/pharmexec/Global/Reading-the-Risk-Radar/ArticleStandard/Article/detail/596955?contextCategoryId=43776&ref=25 Pharm Exec Europe's Gerhard Symons speaks to Andrew Jones, a senior pharmaceutical analyst with the firm, about the value of introducing a "risk radar" to your organization. 2009-05-06T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/192009/596955null HTML http://pharmexec.findpharma.com/pharmexec/Special+Reports/2009-PharmExec-Top-50/ArticleStandard/Article/detail/597526?contextCategoryId=43776&ref=25 We leap tall buildings to bring you the definitive guide to the world's top pharmaceutical companies. 2009-05-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/202009/597526/top50_thumbnail.jpg http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/202009/597526/PE0509_top50_flash.jpg PDF http://pharmexec.findpharma.com/pharmexec/Strategy/The-Shakeout/ArticleStandard/Article/detail/597226?contextCategoryId=43776&ref=25 When it comes to licensing in this market, there are winners and losers. Learn the new rules of the game. 2009-05-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/192009/597226null XML http://pharmexec.findpharma.com/pharmexec/Strategy/Why-All-the-Bad-Buzz/ArticleStandard/Article/detail/597234?contextCategoryId=43776&ref=25 European docs have always been down on pharma—but now the US is catching on. Perhaps pharma has oversold the "service model." 2009-05-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/192009/597234/bad_buzz_thumbnail.jpg http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/192009/597234null XML http://pharmexec.findpharma.com/pharmexec/Strategy/The-Fate-of-Mannkind/ArticleStandard/Article/detail/597228?contextCategoryId=43776&ref=25 Al Mann has sunk almost $1 billion of his own money into a new insulin delivery system. Will FDA be persuaded? 2009-05-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/192009/597228/mannkind_thumbnail.jpg http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/192009/597228null XML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Pharma-Steps-Up-to-Help-With-Swine-Flu/ArticleStandard/Article/detail/595659?contextCategoryId=43776&ref=25 As the US government weighs its options on whether to commission a vaccine for the new H1N1 strain of influenza, pharma companies gear up for a possible epidemic. 2009-04-29T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/182009/595659null HTML http://pharmexec.findpharma.com/pharmexec/Strategy/JampJ-Eliminates-900-Sales-Positions/ArticleStandard/Article/detail/593480?contextCategoryId=43776&ref=25 In an effort to realign its sales division to reflect the current pharma environment—smaller, faster, better—Johnson & Johnson is trimming its sales force. 2009-04-15T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/162009/593480null HTML http://pharmexec.findpharma.com/pharmexec/Online+Only/Post-Employment-Restrictive-Covenants/ArticleStandard/Article/detail/592376?contextCategoryId=43776&ref=25 A company’s trade secrets and the goodwill it has developed can mean the difference between a blockbuster and a failure. Here’s what you should know and do to properly negotiate post-employment agreements. 2009-04-08T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/152009/592376null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Pfizer-Begins-Wyeth-Integration-with-New-Research-/ArticleStandard/Article/detail/592362?contextCategoryId=43776&ref=25 Just two months after the purchase of Wyeth, Pfizer breaks its research division into two—one for large molecules and vaccines, and another for small molecules—with Wyeth and Pfizer execs at the helms. 2009-04-08T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/152009/592362null HTML http://pharmexec.findpharma.com/pharmexec/Strategy/Shire-Joins-with-GSK-to-Promote-ADHD-Drug/ArticleStandard/Article/detail/590836?contextCategoryId=43776&ref=25 Now that Vyvanse, Shire's innovative ADD drug, has been approved for adults, the company needs help to quickly roll out a complex message to neurologists. Its solution: a partnership that takes advantage of GSK's CNS muscle. 2009-04-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/142009/590836null HTML http://pharmexec.findpharma.com/pharmexec/Strategy+Articles/Deborah-Dunsire-Woman-of-the-Year/ArticleStandard/Article/detail/592058?contextCategoryId=43776&ref=25 From her start as a physician working in apartheid-era South Africa to the dramatic turnaround and takeover of Millennium, Deborah Dunsire has lived a life that has defied all expectations. 2009-04-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/152009/592058/PE0409_woty_flash.jpg XML http://pharmexec.findpharma.com/pharmexec/Profiles/Merck-Serono-A-Few-Words-With-Elmar-Schnee/ArticleStandard/Article/detail/590848?contextCategoryId=43776&ref=25 "Best Pharma not Big Pharma" is Merck Serono head Elmar Schnee's business philosophy. He tells Pharm Exec Europe how the Swiss-based company aims to achieve that goal, and points out the current political obstacles. 2009-04-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/142009/590848null HTML http://pharmexec.findpharma.com/pharmexec/Strategy/Prescription-Abandonment-Numbers-on-the-Rise/ArticleStandard/Article/detail/590840?contextCategoryId=43776&ref=25 Compliance woes and stingy insurance providers are walloping the pharmaceutical industry. But now another nuisance is rearing its ugly head, as a high number of patients are ignoring their doctor's orders and dropping their prescriptions on purpose. 2009-04-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/142009/590840null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Lillys-ZyprexaProzac-Combo-Approved-for-Depression/ArticleStandard/Article/detail/589335?contextCategoryId=43776&ref=25 After repeated requests for additional study information, the wait has paid off: Lilly was approved to sell its bipolar drug Symbyax for treatment-resistant depression. 2009-03-25T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/132009/589335null HTML http://pharmexec.findpharma.com/pharmexec/Strategy+Articles/Fifth-Annual-Press-Audit-Safety-in-the-Spotlight/ArticleStandard/Article/detail/585589?contextCategoryId=43776&ref=25 Reporters pass on the typical litany of lightning-rod issues and instead devote more than three-quarters of all coverage in 2008 to drug safety—and the regulators who enforce it. 2009-03-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/102009/585589/PE0309_media_flash.jpg XML http://pharmexec.findpharma.com/pharmexec/Strategy+Articles/Attack-of-the-Monster-Merger/ArticleStandard/Article/detail/585590?contextCategoryId=43776&ref=25 Just when you thought it was safe to go back into M&A, the mega merger returns. What's right about Pfizer-Wyeth, and what's scary. 2009-03-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/102009/585590/PE0309_pfizerwyeth_flash.jpg XML http://pharmexec.findpharma.com/pharmexec/News+Analysis/GSK-and-KV-Downsize-in-the-Wake-of-Q4-Numbers/ArticleStandard/Article/detail/580858?contextCategoryId=43776&ref=25 GlaxoSmithKline to lay off thousands while embattled KV Pharma drops 40 percent of its work force in latest wave of cuts. 2009-02-11T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/072009/580858null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Pharma-Beats-Sunshine-Act-to-the-Punch/ArticleStandard/Article/detail/580863?contextCategoryId=43776&ref=25 Pfizer is the latest addition to Big Pharma's data disclosure club; the drug giant will be disclosing all physician payments that total more that $500 a year. 2009-02-11T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/072009/580863null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/King-Pharma-Purges-22-Percent-of-its-Workforce/ArticleStandard/Article/detail/579468?contextCategoryId=43776&ref=25 Facing patent expiry for one of its top drugs and an overabundance of sales staff due to recent acquisitions, King announced that it would eliminate 760 jobs. 2009-02-04T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/062009/579468null HTML http://pharmexec.findpharma.com/pharmexec/Special+Reports/Vaccines-for-All/ArticleStandard/Article/detail/580042?contextCategoryId=43776&ref=25 The world is suffering. But just over the horizon is a new access equation that could speed innovative vaccines to where they're needed most. 2009-02-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/062009/580042/PE0209_vaccine_flash.jpg XML http://pharmexec.findpharma.com/pharmexec/Strategy+Articles/Stream-Power/ArticleStandard/Article/detail/580043?contextCategoryId=43776&ref=25 Convert future revenue into present value with alternative approaches to access capital. 2009-02-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/062009/580043/PE0209_stream_flash.jpg XML http://pharmexec.findpharma.com/pharmexec/Strategy+Articles/Brand-of-the-Year-Crestor/ArticleStandard/Article/detail/580041?contextCategoryId=43776&ref=25 For aiming to be a game-changer in cardiovascular disease, we recognize comeback kid Crestor as the year's No. 1. Plus three fine finalists. 2009-02-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/062009/580041/PE0209_brand_flash.jpg XML http://pharmexec.findpharma.com/pharmexec/Web+Exclusives/Nycomeds-New-Horizons/ArticleStandard/Article/detail/575348?contextCategoryId=43776&ref=25 Long-standing Nycomed CEO Håkan Björklund tells Pharm Exec Europe how the company is looking to new products, and new territories, to combat the patent expiry of its biggest product. 2009-01-14T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/032009/575348null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Pfizer-Sheds-More-Staff/ArticleStandard/Article/detail/575379?contextCategoryId=43776&ref=25 Sales reps aren't the only ones heading for the unemployment line - Pfizer is eliminating researcher positions as fewer drugs are making it to development. But could streamlining the crux of drug R&D cause more harm than good? 2009-01-14T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/032009/575379null HTML http://pharmexec.findpharma.com/pharmexec/Special+Reports/Forecast-2009-Up-in-the-Air/ArticleStandard/Article/detail/574632?contextCategoryId=43776&ref=25 We know what you're thinking: new president, rotten economy, patent cliff. Do you feel Evel? Well, do you? 2009-01-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/022009/574632/PE0109_forecast_flash.jpg XML http://pharmexec.findpharma.com/pharmexec/Strategy+Articles/Overlooked-Opportunities/ArticleStandard/Article/detail/574630?contextCategoryId=43776&ref=25 "Test and treat" strategies aren't just for new-to-market drugs anymore. 2009-01-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/022009/574630/PE0109_overlooked_flash.jpg XML http://pharmexec.findpharma.com/pharmexec/Strategy+Articles/Pharma-vs-Pharma/ArticleStandard/Article/detail/574631?contextCategoryId=43776&ref=25 Every industry has a life cycle, and pharma's has just entered its competitive stage. Here's how to prepare. 2009-01-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/022009/574631/PE0109_pharmaVSpharma_flash.jpg XML http://pharmexec.findpharma.com/pharmexec/Article/Security-Spotlight-QampA-with-James-Christian-Nova/ArticleStandard/Article/detail/571251?contextCategoryId=43776&ref=25 Pharm Exec talks with James Christian, head of security at Novartis, to learn more about what the company is doing to protect its supply chain and stop counterfeiters 2008-12-11T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/502008/571251null HTML http://pharmexec.findpharma.com/pharmexec/Profiles/Reshaping-Basic-Research-at-Merck/ArticleStandard/Article/detail/571231?contextCategoryId=43776&ref=25 Two years ago, an internal Merck survey revealed that its basic research operation was "every flavor of what you don't want." Today the company is in the midst of implementing a new strategy that groups scientists at sites dedicated to particular clinical areas. VP Kathleen Metters explains why - and how. 2008-12-11T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/502008/571231null HTML http://pharmexec.findpharma.com/pharmexec/Strategy/Merck-Introduces-New-Strategy-BioVentures/ArticleStandard/Article/detail/570615?contextCategoryId=43776&ref=25 At its annual business briefing, Merck surprised analysts with the announcement that it would be launching a new business in the biologics sector in an effort to create generic biotech drugs. 2008-12-10T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/502008/570615null HTML http://pharmexec.findpharma.com/pharmexec/Strategy/Industry-Cuts-Deep-Between-Holidays/ArticleStandard/Article/detail/570616?contextCategoryId=43776&ref=25 It's beginning to look a lot like layoffs. Lilly and Sanofi-Aventis announce sales rep cuts amid an economic downturn and the holiday season. 2008-12-10T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/502008/570616null HTML http://pharmexec.findpharma.com/pharmexec/Special+Reports/The-2008-Pipeline-Report/ArticleStandard/Article/detail/570131?contextCategoryId=43776&ref=25 We scrub industry's pipeline to find the drugs that everyone will be talking about in 2009 and beyond 2008-12-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/492008/570131/PE1208_pipeline_flash.jpg XML http://pharmexec.findpharma.com/pharmexec/Strategy+Articles/The-New-Deals/ArticleStandard/Article/detail/570130?contextCategoryId=43776&ref=25 Everything you wanted to know about the year's most important deals—and what to watch for in the future 2008-12-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/492008/570130/PE1208_deals_flash.jpg XML http://pharmexec.findpharma.com/pharmexec/Strategy+Articles/Keeping-It-Real/ArticleStandard/Article/detail/570132?contextCategoryId=43776&ref=25 Online pharmacies are touting more than just Viagra. Here's what pharma is hoping to do about it 2008-12-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/492008/570132/PE1208_security_flash.jpg XML http://pharmexec.findpharma.com/pharmexec/News+Analysis/From-Europe-to-China-AZ-Restructures-Packing-Strat/ArticleStandard/Article/detail/568238?contextCategoryId=43776&ref=25 AstraZeneca is releasing 1,400 employees in Europe, and refocusing its packing system in an effort to move product closer to where the demand is. In this case, that's China. 2008-11-26T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/482008/568238null HTML http://pharmexec.findpharma.com/pharmexec/Online+Only/Staying-Ahead-of-the-Curve/ArticleStandard/Article/detail/565895?contextCategoryId=43776&ref=25 Significant and dramatic healthcare policy changes are likely to follow after Barack Obama takes the oath of office and the expanded Democratic congressional majority settles in. But what does the electoral outcome mean for healthcare companies and the industry as a whole? 2008-11-13T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/462008/565895null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/CB-1-Antagonists-for-Obesity-RIP/ArticleStandard/Article/detail/565272?contextCategoryId=43776&ref=25 Once considered the future of weight loss drugs, CB-1 antagonists have now been shelved globally. With failures from Pfizer, Merck, and Sanofi-Aventis, analysts say that this is the end of a potential blockbuster therapy. 2008-11-12T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/462008/565272null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Jupiter-Study-Gives-Huge-Boost-to-Crestor/ArticleStandard/Article/detail/565269?contextCategoryId=43776&ref=25 AstraZeneca caused a ruckus at the American Heart Association's annual meeting as data was released proving that its statin not only works for its target indication, but also reduced major CV events in patients who don?t have high cholesterol. 2008-11-12T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/462008/565269null HTML http://pharmexec.findpharma.com/pharmexec/Sales+Articles/The-Mess-in-MS/ArticleStandard/Article/detail/566075?contextCategoryId=43776&ref=25 A five-year forecast of the multiple-sclerosis market following the disruptions of Tysabri 2008-11-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/462008/566075/PE1108_ms_flash.jpg XML http://pharmexec.findpharma.com/pharmexec/Article/Tech-Toys/ArticleStandard/Article/detail/566072?contextCategoryId=43776&ref=25 Here are the hottest gadgets and gizmos to make a dent in drug noncompliance 2008-11-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/462008/566072null XML http://pharmexec.findpharma.com/pharmexec/Strategy+Articles/Pharm-Exec-QampA-Tommy-Thompson/ArticleStandard/Article/detail/566073?contextCategoryId=43776&ref=25 The former health secretary offers a reality check on healthcare reform—and what to expect from the pols in '09 2008-11-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/462008/566073/PE1108_thompson_flash.jpg XML http://pharmexec.findpharma.com/pharmexec/R%26D/Gilding-Lilly/ArticleStandard/Article/detail/566074?contextCategoryId=43776&ref=25 Some say it's just another pharma facing its patent cliff. But others say this company's got it worse. With new CEO John Lechleiter in charge, can Lilly find its way back from the edge? 2008-11-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/462008/566074/PE1108_lilly_flash.jpg XML http://pharmexec.findpharma.com/pharmexec/Online+Only/Merck-Restructures-Eliminates-7200-Jobs/ArticleStandard/Article/detail/561583?contextCategoryId=43776&ref=25 Industry is cinching its belt, but news that Merck will shed 12 percent of its workforce - many senior and middle management positions - was a bombshell announcement. 2008-10-29T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/442008/561583null HTML http://pharmexec.findpharma.com/pharmexec/Strategy/Novartis-Trims-550-Sales-Positions/ArticleStandard/Article/detail/560235?contextCategoryId=43776&ref=25 Novartis is the latest pharma company to move away from the traditional sales model of blanketing sales reps for one drug across the nation. The company is restructuring its force (and cutting jobs) to focus on a regional sales model. 2008-10-22T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/432008/560235null HTML http://pharmexec.findpharma.com/pharmexec/Strategy/Web-Registries-Get-OK-to-Shut-Down-Rogue-Pharmacie/ArticleStandard/Article/detail/560234?contextCategoryId=43776&ref=25 New legislation gives US-based Web hosting companies the go-ahead to remove shady online pharmacies without a warrant. The new rule makes it harder to market counterfeit drugs, and for consumers to purchase medication without a prescription. 2008-10-22T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/432008/560234null HTML http://pharmexec.findpharma.com/pharmexec/Strategy/Norgine-Bails-on-British-Pharmaceutical-Industry/ArticleStandard/Article/detail/558744?contextCategoryId=43776&ref=25 Specialty drug firm Norgine splits from the British pharma association due to a growing rift about pricing. A "war of the roses" is escalating between Big Pharma and smaller drug manufacturers; Norgine could be the first casualty. 2008-10-15T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/422008/558744null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Pfizer-Refocuses-Marketing-Division-with-New-Restr/ArticleStandard/Article/detail/556977?contextCategoryId=43776&ref=25 The pharma giant just announced major plans to break up its R&D divisions into smaller units targeting areas of growth. Marketing will be part of the restructuring plan, and there is good news: No new layoffs. 2008-10-08T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/412008/556977null HTML http://pharmexec.findpharma.com/pharmexec/Strategy+Articles/Getting-Personalized/ArticleStandard/Article/detail/557677?contextCategoryId=43776&ref=25 Stop worrying about shrinking the market for your drug, and start figuring out how the "test and treat" business model works. 2008-10-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/412008/557677/PE1008_personalized_flash.jpg XML http://pharmexec.findpharma.com/pharmexec/Strategy+Articles/The-D-Mab-Men/ArticleStandard/Article/detail/557674?contextCategoryId=43776&ref=25 Amgen's salvation just may be denosumab. We sit down to talk with the head scientists driving the drug. 2008-10-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/412008/557674/PE1008_DmabMen_flash.jpg XML http://pharmexec.findpharma.com/pharmexec/Strategy+Articles/Global-Warming/ArticleStandard/Article/detail/557675?contextCategoryId=43776&ref=25 Japan is playing a game of catch-up, dropping big cash on biotechs and risky acquisitions. But with patents expiring and sales falling, can they really pay their way to global success? 2008-10-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/412008/557675/PE1008_globalwarming_flash.jpg XML http://pharmexec.findpharma.com/pharmexec/Strategy+Articles/Stop-the-Bleeding/ArticleStandard/Article/detail/557678?contextCategoryId=43776&ref=25 Manufacturers overpay PBMs millions of dollars each year in rebates overpayments. Here's how to stop the leakage. 2008-10-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/412008/557678null XML http://pharmexec.findpharma.com/pharmexec/Strategy/Older-Antipsychotic-Drug-Found-Safer-than-New-Trea/ArticleStandard/Article/detail/550566?contextCategoryId=43776&ref=25 A new study from the NIMH shows that next-generation treatments for schizophrenia might not be any better than older, first generation drugs—and in some cases might be worst. 2008-09-17T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/382008/550566null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/GSK-Restructures-Oncology-Division/ArticleStandard/Article/detail/550565?contextCategoryId=43776&ref=25 Glaxo's cancer departments will be consolidated into one big division encompassing discovery, research, and trials. The move is expected to cost some jobs, but GSK hopes it will strengthen synergy within its R&D unit. 2008-09-17T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/382008/550565null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/UCB-Pharma-to-Rebrand-as-Specialty-Company/ArticleStandard/Article/detail/547459?contextCategoryId=43776&ref=25 The Belgium-based drug maker is terminating 2,000 jobs and rebranding itself as a biopharm with a focus on CNS and immunology drugs. Pharm Exec gave UCB a call to find out more. 2008-09-04T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/362008/547459null HTML http://pharmexec.findpharma.com/pharmexec/Strategy/Vytorin-Comes-Under-Fire-Yet-Again/ArticleStandard/Article/detail/547460?contextCategoryId=43776&ref=25 A new study shows that while the combo drug decreases the chance of coronary artery disease, it doesn't work as well in slowing down aortic valve disease. So why is all the focus on cancer deaths? 2008-09-04T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/362008/547460null HTML http://pharmexec.findpharma.com/pharmexec/Article/How-Do-You-Solve-a-Problem-Like-Manufacturing/ArticleStandard/Article/detail/548215?contextCategoryId=43776&ref=25 Outsourcing saves money—except when it doesn't. Here's how to decide what to do. 2008-09-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/372008/548215null XML http://pharmexec.findpharma.com/pharmexec/Strategy/Industry-Audit---Company-of-the-Year-2008/ArticleStandard/Article/detail/550197?contextCategoryId=43776&ref=25 Pharm Exec's 7th annual review of the top companies. We slice and dice the numbers to see who's the best a what. (pdf) 2008-09-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/382008/550197/PE0908_audit_flash.jpg PDF http://pharmexec.findpharma.com/pharmexec/Strategy/Preemption-Makes-Waves-in-Two-More-Cases/ArticleStandard/Article/detail/543114?contextCategoryId=43776&ref=25 The case for preemption gets shot down in Texas, but holds up in yet another Medtronic suit in Minnesota. 2008-08-20T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/342008/543114null HTML http://pharmexec.findpharma.com/pharmexec/Online+Only/Merck-Vaccine-Market-Takes-Center-Stage/ArticleStandard/Article/detail/543115?contextCategoryId=43776&ref=25 Margaret McGlynn, Merck's head of vaccines, expounded yesterday on the state of the company's vaccine program, including campaign strategies, product development, and a new reimbursement program for doctors. 2008-08-20T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/342008/543115null HTML http://pharmexec.findpharma.com/pharmexec/Strategy/Patients-Spurn-AIDS-Drugs-Due-to-Side-Effects/ArticleStandard/Article/detail/534038?contextCategoryId=43776&ref=25 A new study reports that more than 27 percent of Americans are not being treated for HIV because they fear adverse reactions to the drugs. Pharm Exec talked to the doctors in charge of the survey to learn more. 2008-08-06T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/322008/534038null HTML http://pharmexec.findpharma.com/pharmexec/Strategy+Articles/Harbingers-of-Change/ArticleStandard/Article/detail/533845?contextCategoryId=43776&ref=25 The industry is a-changing. Here are eight seminal events that describe how. 2008-08-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/322008/533845/PE0808_harbingers_flash.jpg XML http://pharmexec.findpharma.com/pharmexec/Article/Inside-the-Doughnut-Hole/ArticleStandard/Article/detail/533843?contextCategoryId=43776&ref=25 An answer to your question: What does the Part D coverage gap do to drug sales? 2008-08-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/322008/533843/PE0808_donut_flash.jpg XML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Attention-YouTube-Users-GSK-Wants-You/ArticleStandard/Article/detail/532505?contextCategoryId=43776&ref=25 Glaxo launched a YouTube page targeting potential employees through YouTube. One video in particular features CEO Andrew Witty talking about his adventures in GSK. Is this the future of recruitment? 2008-07-30T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/312008/532505null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Pharma-CEOs-Expound-on-Industry-Change/ArticleStandard/Article/detail/527131?contextCategoryId=43776&ref=25 A new global CEO study examines what near- and long-term changes pharma leaders expect to face and in what areas they are planning to focus their attention. Key focus areas: global business design and new markets. 2008-07-02T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/272008/527131null HTML http://pharmexec.findpharma.com/pharmexec/Rotating+Feature+Article/RNA-Revolutionaries/ArticleStandard/Article/detail/529152?contextCategoryId=43776&ref=25 Could gene silencing be the next great innovation in drug development? Some biotechs are betting on it. 2008-07-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/282008/529152/rpRNAi_flash.jpg XML http://pharmexec.findpharma.com/pharmexec/Rotating+Feature+Article/Pharmas-Day-in-Court/ArticleStandard/Article/detail/529151?contextCategoryId=43776&ref=25 A look at some of the court cases that could actually change the pharma playing field 2008-07-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/282008/529151/rpCourt_flash.jpg XML http://pharmexec.findpharma.com/pharmexec/Online+Only/New-Plant-Means-New-Jobs/ArticleStandard/Article/detail/525746?contextCategoryId=43776&ref=25 Merck bolsters vaccine making division with the addition of 400 new employees to fill its new manufacturing plant. 2008-06-25T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/262008/525746null HTML http://pharmexec.findpharma.com/pharmexec/Strategy/Sanofi-Aventis-to-Trim-Sales-Force/ArticleStandard/Article/detail/522922?contextCategoryId=43776&ref=25 French drugmaker to cut 800 jobs, joining the long list of companies restructuring to make ends meet. 2008-06-11T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/242008/522922null HTML http://pharmexec.findpharma.com/pharmexec/Rotating+Feature+Article/Stealth-Pharmas/ArticleStandard/Article/detail/523688?contextCategoryId=43776&ref=25 Second annual Not Big Pharma audit gives equal time to the little guys. Who's got the Midas touch? 2008-06-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/242008/523688/stealthpharma_flash.jpg XML http://pharmexec.findpharma.com/pharmexec/Rotating+Feature+Article/45-Under-45The-Change-Generation/ArticleStandard/Article/detail/524375?contextCategoryId=43776&ref=25 In our first ever Emerging Leadership Awards, we profile 45 talented young professionals who will lead pharma into the next generation 2008-06-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/252008/524375/45under45_flash.jpg XML http://pharmexec.findpharma.com/pharmexec/Articles/Being-Bob-QampA-with-Robert-Essner/ArticleStandard/Article/detail/523689?contextCategoryId=43776&ref=25 An industry legend weighs in on leadership, research, and sales models. Q&A with outgoing Wyeth Chairman Bob Essner 2008-06-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/242008/523689null XML